Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Predicting the future of advanced prostate cancer.

Sørensen KD.

Lancet Oncol. 2012 Nov;13(11):1067-8. doi: 10.1016/S1470-2045(12)70398-4. Epub 2012 Oct 9. No abstract available.

PMID:
23059048
2.

Words of wisdom: re: prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

Maitland NJ.

Eur Urol. 2013 Aug;64(2):341-2. doi: 10.1016/j.eururo.2013.05.014. No abstract available.

PMID:
23830230
3.

Prostate cancer biomarker: a key field to explore.

Lin J, Yang H, Kelly WK.

Asian J Androl. 2013 May;15(3):358-9. doi: 10.1038/aja.2013.1. Epub 2013 Feb 25. No abstract available.

4.

mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer.

Cann GM, Gulzar ZG, Cooper S, Li R, Luo S, Tat M, Stuart S, Schroth G, Srinivas S, Ronaghi M, Brooks JD, Talasaz AH.

PLoS One. 2012;7(11):e49144. doi: 10.1371/journal.pone.0049144. Epub 2012 Nov 7.

5.

[Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].

Ohori M.

Gan To Kagaku Ryoho. 2009 Jan;36(1):6-10. Review. Japanese.

PMID:
19151558
6.
7.

Editorial comment on: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.

Cooper C.

Eur Urol. 2008 Nov;54(5):1107-8. Epub 2007 Nov 26. No abstract available.

PMID:
18061340
8.

Editorial comment on: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.

Valentini A, Bernardini S.

Eur Urol. 2008 Nov;54(5):1106-7. Epub 2007 Nov 26. No abstract available.

PMID:
18061338
9.

Telomerase mRNA detection in serum of patients with prostate cancer.

Dalle Carbonare L, Gasparetto A, Donatelli L, Dellantonio A, Valenti MT.

Urol Oncol. 2013 Feb;31(2):205-10. doi: 10.1016/j.urolonc.2010.12.017. Epub 2011 Feb 25.

PMID:
21353795
10.

[RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].

Okubo Y, Ito T.

Hinyokika Kiyo. 1999 Jan;45(1):25-30. Japanese.

11.

Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: a preliminary study.

Pipinikas CP, Nair SB, Kirby RS, Carter ND, Fenske CD.

Biomarkers. 2007 Sep-Oct;12(5):541-57.

PMID:
17701752
12.

Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer.

Gao X, Grignon DJ, Chbihi T, Zacharek A, Chen YQ, Sakr W, Porter AT, Crissman JD, Pontes JE, Powell IJ, et al.

Urology. 1995 Aug;46(2):227-37.

PMID:
7624992
13.

Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.

Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C.

Clin Cancer Res. 1999 May;5(5):977-83.

14.

A review of expression profiling of circulating microRNAs in men with prostate cancer.

Kelly BD, Miller N, Healy NA, Walsh K, Kerin MJ.

BJU Int. 2013 Jan;111(1):17-21. doi: 10.1111/j.1464-410X.2012.11244.x. Epub 2012 May 22. Review.

15.

WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.

Lin B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS, Hood L, Kalland KH, Akslen LA.

Clin Cancer Res. 2008 Mar 1;14(5):1397-406. doi: 10.1158/1078-0432.CCR-07-1535.

16.

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.

Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK.

Lancet Oncol. 2012 Nov;13(11):1105-13. doi: 10.1016/S1470-2045(12)70263-2. Epub 2012 Oct 9.

PMID:
23059047
18.

Telomerase expression as a marker in prostate cancer: correlation to clinicopathologic predictors.

Athanassiadou P, Bantis A, Gonidi M, Liossi A, Aggelonidou E, Petrakakou E, Giannopoulos A.

J Exp Clin Cancer Res. 2003 Dec;22(4):613-8.

PMID:
15053304
19.

CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.

Kristiansen G, Pilarsky C, Pervan J, Stürzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M.

Prostate. 2004 Feb 1;58(2):183-92.

PMID:
14716744
20.

Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma.

Kunter U, Buer J, Probst M, Duensing S, Dallmann I, Grosse J, Kirchner H, Schluepen EM, Volkenandt M, Ganser A, Atzpodien J.

J Natl Cancer Inst. 1996 May 1;88(9):590-4.

PMID:
8609659

Supplemental Content

Support Center